Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysis: Focus on Dosage Form, Country and Regional Analysis - Analysis and Forecast, ...

The last time I wrote about Allogene Therapeutics, Inc. (ALLO) it was in a Seeking Alpha article entitled "Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products." I noted the ...

Less than half of the healthcare providers correctly identified refractory chronic cough (RCC) as a cough lasting more than 8 weeks and not responding to treatment, based on survey data from more than ...

Former Valley Center High School and San Diego State quarterback Kevin Craft has been named head football coach at Riverside City College, taking over for his father Tom, who retired at the end of ...

RCC is a short-term, exchange-listed baby bond from Ready Capital, maturing in February 2026, offering an 8.5% yield to maturity. The bond's very short duration minimizes market risk, making solvency ...

Partial nephrectomy was associated with the highest survival rate among patients with localized RCC aged 75 years and older compared with radical nephrectomy, ablation, and surveillance. Despite its ...

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification. The phase 3 COSMIC-313 trial evaluated Cabometyx ...

RCC trials are predominantly in high-income countries, limiting access for lower-income patients and affecting global treatment strategies. Minority groups, especially Black and Hispanic populations, ...

A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to early ...

Exceptional responses in RCC are associated with higher clonal neoantigen load and enriched B-cell receptor signaling pathways. Tertiary lymphoid structure signatures and increased metabolic activity ...

LOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small ...